Dr. Jeremy Levin: Why Biotech Is Not Big Pharma

Dr. Jeremy Levin, founder of Ovid Therapeutics, discusses the critical role of biotechnology in healthcare reform and public health policy on the Health Policy Podcast. He emphasizes the importance of patient advocacy and the need for a strategic approach to biotech in the United States.

WASHINGTON — July 7, 2026 — Dr. Jeremy Levin, founder of Ovid Therapeutics, appeared on the Health Policy Podcast to discuss the significance of biotechnology in healthcare reform, public health policy, and patient advocacy. The episode highlights the challenges facing the biotech industry and the need for renewed trust among patients and policymakers.

Dr. Levin noted that 70% of new drugs originate from biotech, underscoring the industry's vital role in medical innovation. He warned that a growing distrust in the pharmaceutical sector could hinder progress in biotechnology. "Distrust starts to creep. And that is where the real problem starts for the industry," he said.

He called for a shift in how biotech is perceived, advocating for its designation as a national strategic asset. "We need to make biotech a national strategic asset, just like housing, just like defense," Dr. Levin stated. He emphasized that without this recognition, essential advancements in science and regulatory processes may not materialize.

Ovid Therapeutics is a biopharmaceutical company focused on developing innovative therapies for patients with rare neurological disorders. The company aims to advance treatments that improve the quality of life for patients and their families.

About the Health Policy Podcast

The Health Policy Podcast explores critical issues in healthcare, energy, infrastructure, and economic growth. The show features expert interviews and discussions that aim to inform listeners about the complexities of health policy and its impact on society.